|
Markers
|
Categories
|
All stages
|
Stage I and II
|
Stage III
|
Stage IV
|
P for interaction
|
|---|
|
ndeath/ncases
|
HR (95% CI)*
|
ndeath/ncases
|
HR (95% CI)#
|
ndeath/ncases
|
HR (95% CI)#
|
ndeath/ncases
|
HR (95% CI)#
|
|---|
|
AgeAccelHorvath
|
Tertile 1
|
361/736
|
1.00 (Ref.)
|
135/364
|
1.00 (Ref.)
|
124/260
|
1.00 (Ref.)
|
100/107
|
1.00 (Ref.)
|
–
|
|
Tertile 2
|
339/736
|
1.01 (0.86, 1.18)
|
138/402
|
0.97 (0.76, 1.24)
|
109/236
|
0.95 (0.73, 1.25)
|
87/92
|
1.14 (0.83, 1.55)
|
–
|
|
Tertile 3
|
379/734
|
1.17 (0.99, 1.38)
|
163/393
|
1.32 (1.04, 1.38)
|
117/230
|
1.18 (0.90, 1.55)
|
98/110
|
0.98 (0.71, 1.34)
|
–
|
|
Per SD increase
|
1079/2206
|
1.06 (0.99, 1.13)
|
436/1159
|
1.10 (0.99, 1.21)
|
350/726
|
1.10 (0.99, 1.23)
|
285/309
|
0.96 (0.84, 1.10)
|
0.139
|
|
AgeAccelHannum
|
Tertile 1
|
327/736
|
1.00 (Ref.)
|
128/386
|
1.00 (Ref.)
|
124/268
|
1.00 (Ref.)
|
74/80
|
1.00 (Ref.)
|
–
|
|
Tertile 2
|
340/736
|
0.93 (0.78, 1.09)
|
126/387
|
0.89 (0.69, 1.15)
|
109/235
|
0.93 (0.70, 1.24)
|
103/111
|
0.86 (0.60, 1.24)
|
–
|
|
Tertile 3
|
412/734
|
1.12 (0.94, 1.33)
|
182/386
|
1.18 (0.91, 1.53)
|
117/223
|
1.14 (0.84, 1.55)
|
108/118
|
0.91 (0.62, 1.34)
|
–
|
|
Per SD increase
|
1079/2206
|
1.06 (0.98, 1.14)
|
436/1159
|
1.05 (0.93, 1.17)
|
350/726
|
1.11 (0.98, 1.26)
|
285/309
|
1.00 (0.86, 1.17)
|
0.475
|
|
DNAmMRscore
|
Tertile 1
|
275/736
|
1.00 (Ref.)
|
102/410
|
1.00 (Ref.)
|
97/242
|
1.00 (Ref.)
|
76/84
|
1.00 (Ref.)
| |
|
Tertile 2
|
346/736
|
1.07 (0.89, 1.30)
|
147/399
|
1.27 (0.94, 1.70)
|
104/231
|
0.97 (0.71, 1.34)
|
92/102
|
0.89 (0.61, 1.29)
| |
|
Tertile 3
|
458/734
|
1.66 (1.32, 2.09)
|
187/350
|
2.01 (1.42, 2.85)
|
149/253
|
1.64 (1.13, 2.38)
|
117/123
|
1.33 (0.87, 2.04)
|
–
|
|
Per SD increase
|
1079/2206
|
1.34 (1.20, 1.49)
|
436/1159
|
1.50 (1.28, 1.76)
|
350/726
|
1.39 (1.18, 1.64)
|
285/309
|
1.09 (0.90, 1.33)
|
0.616
|
|
AgeAccelPheno
|
Tertile 1
|
318/736
|
1.00 (Ref.)
|
122/390
|
1.00 (Ref.)
|
123/263
|
1.00 (Ref.)
|
71/80
|
1.00 (Ref.)
|
–
|
|
Tertile 2
|
323/736
|
1.02 (0.86, 1.20)
|
126/395
|
0.89 (0.68, 1.15)
|
99/234
|
0.92 (0.69, 1.22)
|
96/102
|
1.43 (1.02, 2.01)
|
–
|
|
Tertile 3
|
438/734
|
1.35 (1.14, 1.59)
|
188/374
|
1.50 (1.17, 1.92)
|
128/229
|
1.28 (0.98, 1.69)
|
118/127
|
1.31 (0.93, 1.86)
|
–
|
|
Per SD increase
|
1079/2206
|
1.18 (1.10, 1.27)
|
436/1159
|
1.22 (1.11, 1.35)
|
350/726
|
1.20 (1.07, 1.35)
|
285/309
|
1.12 (0.97, 1.30)
|
0.459
|
|
AgeAccelGrim
|
Tertile 1
|
286/736
|
1.00 (Ref.)
|
98/405
|
1.00 (Ref.)
|
119/258
|
1.00 (Ref.)
|
68/72
|
1.00 (Ref.)
|
–
|
|
Tertile 2
|
347/736
|
1.13 (0.94, 1.34)
|
144/381
|
1.34 (1.00, 1.78)
|
106/246
|
0.98 (0.73, 1.32)
|
95/104
|
0.95 (0.66, 1.37)
|
–
|
|
Tertile 3
|
446/734
|
1.65 (1.37, 2.00)
|
194/373
|
2.30 (1.69, 3.13)
|
125/222
|
1.63 (1.19, 2.22)
|
122/133
|
1.01 (0.71, 1.45)
|
–
|
|
Per SD increase
|
1079/2206
|
1.35 (1.24, 1.47)
|
436/1159
|
1.48 (1.31, 1.66)
|
350/726
|
1.24 (1.08, 1.43)
|
285/309
|
1.23 (1.05, 1.44)
|
0.082
|
- AgeAccel, age acceleration; CI, confidence interval; DNAm, DNA methylation; HR, hazard ratio; MRscore, mortality risk score
- Numbers printed in bold: statistically significantly different from 1 (P < 0.05)
- *Overall HR was adjusted for age, sex, batch effects, tumor stage and leukocyte composition (Houseman’s algorithm)
- #Stage-specific HR was adjusted for age, sex, batch effects and leukocyte composition (Houseman’s algorithm)
